Therapeutic potential of phages in autoimmune liver diseases

Clinical and Experimental Immunology

Volumn 192, Issue 1, 2018, Pages 1-6

  Gorski A ^a,b   Jonczyk Matysiak E ^a   Lusiak Szelachowska M ^a   Weber Dabrowska B ^a   Miedzybrodzki R ^a,b   Borysowski, J ^b  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

hepatitis; interleukin 10; Kupffer cells; phage; reactive oxygen species

Indexed keywords

ANTIINFLAMMATORY AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR 4; IL10 PROTEIN, HUMAN; IL1RN PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; TLR4 PROTEIN, HUMAN;

AUTOIMMUNE LIVER DISEASE; BACTERIOPHAGE; DOWN REGULATION; ENZYME ACTIVATION; GENE EXPRESSION; HOMEOSTASIS; HUMAN; IMMUNOTHERAPY; KUPFFER CELL; LIVER INJURY; NONHUMAN; PHAGE THERAPY; PRIORITY JOURNAL; REVIEW; SAFETY; THROMBOCYTE; UPREGULATION; VIRUS HEPATITIS; ANIMAL; AUTOIMMUNE DISEASE; GENETICS; IMMUNOLOGY; IMMUNOMODULATION; INFLAMMATION; LIVER DISEASE; METABOLISM; MOUSE; SIGNAL TRANSDUCTION;

ANIMALS; AUTOIMMUNE DISEASES; BACTERIOPHAGES; DOWN-REGULATION; HUMANS; IMMUNOMODULATION; INFLAMMATION; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-10; LIVER DISEASES; MICE; NF-KAPPA B; PHAGE THERAPY; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4;

EID: 85040867843     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.13092     Document Type: Review

References (64)

1. Washington MK. ALD: overlap and outliers. Modern Pathol 2007; 20:515–30.
2. Liwinski T, Schramm C. Autoimmune hepatitis – update on clinical management in 2017. Clin Res Hepatol Gastroenterol 2017; 41: 617–25.
3. Trivedi PJ, Hirschfield GM. Treatment of autoimmune liver disease: current and future therapeutic options. Ther Adv Chronic Dis 2013; 4:119–41.
4. Hey P, Lokan J, Johnson P, Gow P. Efficacy of oral vancomycin in recurrent primary sclerosing cholangitis following liver transplantation. BMJ Case Rep 2017; 2017: bcr-2017–221165.
5. Chapman JR, Webster AC, Wong G. Cancer in the transplant recipient. Cold Spring Harb Perspect Med 2013; 3:a015677.
6. Borysowski J, Górski A. Is phage therapy acceptable in the immunocompromised host? Int J Infect Dis 2008; 12:466–71.
7. Międzybrodzki R, Fortuna W, Weber-Dąbrowska B, Górski A. Bacterial viruses versus viruses pathgenic for man? Virus Res 2005; 110:1–8.
8. Dąbrowska K, Opolski A, Wietrzyk J et al. Antitumor activity of bacteriophages in murine experimental cancer models caused possibly by inhibition of beta3 integrin signaling pathway. Acta Virol 2004; 48:241–8.
9. Dąbrowska K, Opolski A, Wietrzyk J et al. Anticancer activity of bacteriophage T4 and its mutant HAP1 in mouse experimental tumour models. Anticancer Res 2004; 24:3991–5.
10. Lyon J. Phage therapy's role in combating antibiotic-resistant pathogens. JAMA 2017; 318:1746–8.
11. Górski A, Dąbrowska K, Międzybrodzki R et al. Phages and immunomodulation. Future Microbiol 2017; 12:905–14.
12. Międzybrodzki R, Borysowski J, Kłak M et al. In vivo studies on the influence of bacteriophage preparations on the autoimmune inflammatory process. Biomed Res Int 2017; 2017:1.
13. Górski A, Kniotek M, Perkowska-Ptasińska A et al. Bacteriophages and transplantation tolerance. Transpl Proc 2006; 38:331–3.
14. Górski A, Międzybrodzki R, Borysowski J et al. Phage as a modulator of immune response: practical implications for phage therapy. Adv Virus Res 2012; 83:41–71.
15. Barr JJ. A bacteriophage journey through the human body. Immunol Rev 2017; 279:106–22.
16. Górski A, Jończyk-Matysiak E, Łusiak-Szelachowska M et al. Bacteriophages targeting intestinal epithelial cells: a potential novel form of immunotherapy. Cell Mol Life Sci 2017; doi: 10.1007/s00018-017-2715-6.
17. Barr JJ, Auro R, Furlan M et al. Bacteriophage adhering to mucus provide a non-host derived immunity. Proc Nat Acad Sci USA 2013; 110:10771–6.
18. Gorski A, Weber-Dąbrowska B. The potential role of endogenous phages in controlling invading pathogens. Cell Mol Life Sci 2005; 62:511–9.
19. Górski A, Międzybrodzki R, Weber-Dębrowska B et al. Phage therapy: combating infections with potential for evolving from merely a treatment for complications to tageting diseases. Front Microbiol 2016; 7:1515.
20. Miernikiewicz P, Kłopot A, Soluch R et al. T4 phage tail adhesin gp12 counteracts LPS induced inflammation in vivo. Front Microbiol 2016; 7:1112.
21. Roach DR, Leung CY, Henry M et al. Synergy between the host immune system and bacteriophage is essential for successful phage therapy against an acute respiratory pathogen. Cell Host Microbe 2017; 22:38–47.e4.
22. Borysowski J, Międzybrodzki R, Wierzbicki P et al. A3R phage and Staphylococcus aureus lysate do not induce neutrophil degranulation. Viruses 2017; 9:E36.
23. Międzybrodzki R, Fortuna W, Weber-Dąbrowska B, Górski A. A retrospective analysis of changes in inflammatory markers in patients treated with bacterial viruses. Clin Exp Med 2009; 9:303–12.
24. Miedzybrodzki R, Switala-Jelen K, Fortuna W et al. Bacteriophage preparation inhibition of reactive oxygen species generation by endotoxin-stimulated polymorphonuclear leukocytes. Virus Res 2008; 131:233–42.
25. Van Belleghem JD, Clement F, Mrabishvili M et al. Pro- and anti-inflammatory responses of peripheral blond mononuclear cells induced by S. aureus and P. aeruginosa phages. Sci Rep 2017; 7:8001.
26. Krenkel O, Tacke F. Liver macrophages in tissue homeostasis and disease. Nat Rev Immunol 2017; 17:306–21.
27. Tiegs G, Lohse AW. Immune tolerance: what is unique about the liver. J Autoimmun 2010; 34:1–6.
28. Breous E, Somanathan S, Vandenberghe LH, Wilson JM. Hepatic regulatory T cells and Kupffer cells are crucial mediators of systemic T cell tolerance to antigens targeting murine liver. Hepatology 2009; 50:612–21.
29. Heymann F, Peusquens J, Ludwig-Portugall I et al. Liver inflammation abrogates immunological tolerance induced by Kupffer cells. Hepatology 2015; 62:279–91.
30. de Araujo RF Jr, Reinaldo MP, Brito GA et al. Olmesartan decreased levels of IL-1β and TNF-α, down-regulated MMP-2, MMP-9, COX-2, RANK/RANKL and up-regulated SOCs-1 in an intestinal mucositis model. PLOS ONE 2014; 9:e114923.
31. Kakinuma Y, Kimura T, Watanabe Y. Possible involvement of liver resident macrophages (Kupffer cells) in the pathogenesis of both intrahepatic and extrahepatic inflammation. Can J Gastroenterol Hepatol 2017; 2017:2896809.
32. Karimi MH, Geramizadeh B, Malek-Hosseini SA. Tolerance induction in liver. Int J Organ Transplant Med 2015; 6:45–54.
33. Ruiz R, Kunitake H, Wilkinson AH et al. Long-term analysis of combined liver and kidney transplantation at a single center. Arch Surg 2006; 141:735–41.
34. Lopez ML, Uribe-Cruz C, Osvaldt A et al. Encapsulated platelets modulate kupffer cell activation and reduce oxidative stress in a model of acute liver failure. Liver Transpl 2016; 22:1562–72.
35. Zhang M, Xu S, Han Y, Cao X. Apoptotic cells attenuate fulminant hepatitis by priming Kupffer cells to produce interleukin-10 through membrane-bound TGF-β. Hepatology 2011; 53:306–16.
36. Inchley CJ. The activity of mouse Kupffer cells following intravenous injection of bacteriophage. Clin Exp Immunol 1969; 5:173–87.
37. Dąbrowska K, Świtała-Jeleń K, Opolski A et al. Bacteriophage penetration in vertebrates. J Appl Microbiol 2005; 98:7–13.
38. Inchley CJ, Howard JG. The immunogenicity of phagocytosed T4 bacteriophage: cell replacement studies with splenectomized and irradiated mice. Clin Exp Immunol 1969; 5:189–98.
39. Ferrini U, Mileo AM, Nista A et al. Polymorphonuclear leukocyte stimulation measured by phage inactivation. Int Arch Allergy Appl Immunol 1989; 90:207–12.
40. Zhang LJ, Wang XZ. Interleukin-10 and chronic liver disease. World J Gastroenterol 2006; 12:1681–5.
41. Abel M, Sène D, Pol S et al. Intrahepatic virus-specific IL-10 producing CD8+ T cells present liver damage during chronic hepatitis C virus infection. Hepatology 2006; 44:1607–16.
42. Luedde T, Schwabe RF. NF-kappa B in liver injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2011; 8:108–18.
43. Hong M, Li S, Wang N et al. A biomedical investigation of the hepatoprotective effect of radix salviae miltiorrhizae and network pharmacology-based prediction of the active compounds and molecular targets. Int J Mol Sci 2017; 18:E620.
44. Martin-Dominguez V, Vilar-Gomez E, Garcia-Buey L et al. Oxidative stress in autoimmune liver disease. In: Albano E, Parola M, eds. Studies on hepatic disorders. New York, NY: Humana Press, 2015:325–43.
45. Gramantieri L, Casali A, Trere D et al. Imbalance of IL-1 beta and IL-1 receptor antagonist mRNA in liver tissue from hepatitis C virus (HCV)-related chronic hepatitis. Clin Exp Immunol 1999; 115:515–20.
46. Naveau S, Emilie D, Borotto E et al. Interleukin-1 receptor antagonist plasma concentration is specifically increased by alpha-2A-interferon treatment. J Hepatol 1997; 27:272–5.
47. Weber SN, Bohner A, Dapito DH et al. TLR4 deficiency protects against hepatic fibrosis and diethylnitrosamine-induced pre-carcinogenic liver injury in fibrotic liver. PLOS ONE 2016; 11:e0158819.
48. Soares JB, Pimentel-Nunes P, Roncon-Albuquerque R, Leite-Moreira A. The role of lipopolysaccharide/Toll-like receptor 4 signaling in chronic liver diseases. Hepatol Int 2010; 4:659–72.
49. Kiziltas S. Toll-like receptors in pathophysiology of liver diseases. World J Hepatol 2016; 8:1354–69.
50. Chauhan A, Adams DH, Watson SP, Lalor PF. Platelets: no longer bystanders in liver disease. Hepatology 2016; 64:1774–84.
51. Sitia G, Aiolfi R, Di Lucia P et al. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc Natl Acad Sci USA 2012; 109:E2165–72.
52. Neubauer K, Knittel T, Armbrust T, Ramadori G. Accumulation and cellular localization of fibrinogen/fibrin during short-term and long-term rat liver injury. Gastroenterology 1995; 108:1124–35.
53. Mattner J. Impact of microbiome on the pathogenesis of primary biliary cirrhosis and primary sclerosing cholangitis. Int J Mol Sci 2016; 9:17.
54. Iizuka A, Watanabe T, Kubo T et al. M13 bacteriophage DNA inhibits duck hepatitis B virus during acute infection. Hepatology 1994; 19:1079–87.
55. Przybylski M, Borysowski J, Jakubowska-Zahorska R et al. T4 bacteriophage-mediated inhibition of adsorption and replication of human adenovirus in vitro. Future Microbiol 2015; 10:456–60.
56. Schubbert R, Renz D, Schmitz B, Doerfler W. Foreign (M13) DNA ingested by mice reaches peripheral leukocytes, spleen, and liver via the intestinal wall mucosa and can be covalently linked to mouse DNA. Proc Natl Acad Sci USA 1997; 94:961–6.
57. Bakhshinejad B, Sadeghizadeh M. Bacteriophages and their applications in the diagnosis and treatment of hepatitis B virus infection. World J Gastroenterol 2014; 20:11671–83.
58. Sarker SA, McCallin S, Barretto C et al. Oral T4-like phage cocktail application to healthy adult volunteers from Bangladesh. Virology 2012; 434:222–32.
59. Międzybrodzki R, Borysowski J, Weber-Dąbrowska B et al. Clinical aspects of phage therapy. Adv Virus Res 2012; 83:73–121.
60. Sarker SA, Berger B, Deng Y et al. Oral application of Escherichia coli bacteriophage: safety tests in healthy and diarrheal children from Bangladesh. Environ Microbiol 2017; 19:237–50.
61. Hung CH, Kuo CF, Wang CH et al. Experimental phage therapy in treating Klebsiella pneumoniae-mediated liver abscesses and bacteremia in mice. Antimicrob Agents Chemother 2011; 55:1358–65.
62. Wang JP, Yan L, Lee JH, Kim IH. Evaluation of bacteriophage supplementation on growth performance, blood characteristics, relative organ weight, breast muscle characteristics and excreta microbial shedding in broilers. Asian-Australas J Anim Sci 2013; 26:573–8.
63. Selmi C, Generali E, Gershwin ME. Rheumatic manifestations in autoimmune liver disease. Rheum Dis Clin North Am 2018; 44:65–87.
64. Sirpal S, Chandok N. Primary sclerosing cholangitis: diagnostic and management challenges. Clin Exp Gastroenterol 2017; 10:265–73.